Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform
Executive Summary
In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises